130 related articles for article (PubMed ID: 32860848)
1. Knockdown of RhoGDI2 represses human gastric cancer cell proliferation, invasion and drug resistance via the Rac1/Pak1/LIMK1 pathway.
Zeng Y; Ren M; Li Y; Liu Y; Chen C; Su J; Su B; Xia H; Liu F; Jiang H; Ling H; Zeng X; Su Q
Cancer Lett; 2020 Nov; 492():136-146. PubMed ID: 32860848
[TBL] [Abstract][Full Text] [Related]
2. Diallyl disulfide downregulating RhoGDI2 induces differentiation and inhibit invasion via the Rac1/Pak1/LIMK1 pathway in human leukemia HL-60 cells.
Hui T; Yiling J; Guangqun C; Ran L; Hui L; Lan Y; Jie H; Su Q
Environ Toxicol; 2023 May; 38(5):1063-1077. PubMed ID: 36793247
[TBL] [Abstract][Full Text] [Related]
3. Diallyl disulfide suppresses epithelial-mesenchymal transition, invasion and proliferation by downregulation of LIMK1 in gastric cancer.
Su B; Su J; Zeng Y; Liu F; Xia H; Ma YH; Zhou ZG; Zhang S; Yang BM; Wu YH; Zeng X; Ai XH; Ling H; Jiang H; Su Q
Oncotarget; 2016 Mar; 7(9):10498-512. PubMed ID: 26871290
[TBL] [Abstract][Full Text] [Related]
4. VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance.
Cho HJ; Kim IK; Park SM; Baek KE; Nam IK; Park SH; Ryu KJ; Choi J; Ryu J; Hong SC; Jeong SH; Lee YJ; Ko GH; Kim J; Won Lee C; Soo Kang S; Yoo J
Int J Cancer; 2014 Oct; 135(7):1553-63. PubMed ID: 24585459
[TBL] [Abstract][Full Text] [Related]
5. DADS downregulates the Rac1-ROCK1/PAK1-LIMK1-ADF/cofilin signaling pathway, inhibiting cell migration and invasion.
Zhou Y; Su J; Shi L; Liao Q; Su Q
Oncol Rep; 2013 Feb; 29(2):605-12. PubMed ID: 23233092
[TBL] [Abstract][Full Text] [Related]
6. RhoGDI2 promotes epithelial-mesenchymal transition via induction of Snail in gastric cancer cells.
Cho HJ; Park SM; Kim IK; Nam IK; Baek KE; Im MJ; Yoo JM; Park SH; Ryu KJ; Han HT; Kim HJ; Hong SC; Kim KD; Pak Y; Kim JW; Lee CW; Yoo J
Oncotarget; 2014 Mar; 5(6):1554-64. PubMed ID: 24721928
[TBL] [Abstract][Full Text] [Related]
7. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
[TBL] [Abstract][Full Text] [Related]
8. p120-catenin participates in the progress of gastric cancer through regulating the Rac1 and Pak1 signaling pathway.
Li TF; Qin SH; Ruan XZ; Wang X
Oncol Rep; 2015 Nov; 34(5):2357-64. PubMed ID: 26324182
[TBL] [Abstract][Full Text] [Related]
9. RhoGDI2 is expressed in human trophoblasts and involved in their migration by inhibiting the activation of RAC1.
Liu S; Cui H; Li Q; Zhang L; Na Q; Liu C
Biol Reprod; 2014 Apr; 90(4):88. PubMed ID: 24554735
[TBL] [Abstract][Full Text] [Related]
10. Proteomics-based strategy to delineate the molecular mechanisms of RhoGDI2-induced metastasis and drug resistance in gastric cancer.
Cho HJ; Baek KE; Kim IK; Park SM; Choi YL; Nam IK; Park SH; Im MJ; Yoo JM; Ryu KJ; Oh YT; Hong SC; Kwon OH; Kim JW; Lee CW; Yoo J
J Proteome Res; 2012 Apr; 11(4):2355-64. PubMed ID: 22364609
[TBL] [Abstract][Full Text] [Related]
11. 14-3-3σ attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.
Kim IK; Park SM; Cho HJ; Baek KE; Nam IK; Park SH; Ryu KJ; Ryu J; Choi J; Hong SC; Kim JW; Lee CW; Kang SS; Yoo J
Oncotarget; 2013 Nov; 4(11):2045-56. PubMed ID: 24185104
[TBL] [Abstract][Full Text] [Related]
12. PLCγ is required for RhoGDI2-mediated cisplatin resistance in gastric cancer.
Cho HJ; Baek KE; Nam IK; Park SM; Kim IK; Park SH; Im MJ; Ryu KJ; Yoo JM; Hong SC; Kim JW; Lee CW; Yoo J
Biochem Biophys Res Commun; 2011 Oct; 414(3):575-80. PubMed ID: 21986528
[TBL] [Abstract][Full Text] [Related]
13. RhoC Is an Unexpected Target of RhoGDI2 in Prevention of Lung Colonization of Bladder Cancer.
Griner EM; Dancik GM; Costello JC; Owens C; Guin S; Edwards MG; Brautigan DL; Theodorescu D
Mol Cancer Res; 2015 Mar; 13(3):483-92. PubMed ID: 25516960
[TBL] [Abstract][Full Text] [Related]
14. RhoGDI2 is associated with HGF-mediated tumor invasion through VEGF in stomach cancer.
Koh SA; Kim MK; Lee KH; Kim SW; Kim JR
Clin Exp Metastasis; 2014 Oct; 31(7):805-15. PubMed ID: 25253431
[TBL] [Abstract][Full Text] [Related]
15. Rho GDP dissociation inhibitor beta promotes cell proliferation and invasion by modulating the AKT pathway in hepatocellular carcinoma.
Fang Y; Yi J; Lizhi L; Qiucheng C
DNA Cell Biol; 2014 Nov; 33(11):781-6. PubMed ID: 25180836
[TBL] [Abstract][Full Text] [Related]
16. RhoGDI2 confers gastric cancer cells resistance against cisplatin-induced apoptosis by upregulation of Bcl-2 expression.
Cho HJ; Baek KE; Park SM; Kim IK; Nam IK; Choi YL; Park SH; Im MJ; Choi J; Ryu J; Kim JW; Lee CW; Kang SS; Yoo J
Cancer Lett; 2011 Dec; 311(1):48-56. PubMed ID: 21752536
[TBL] [Abstract][Full Text] [Related]
17. RhoGDI2 expression is associated with tumor growth and malignant progression of gastric cancer.
Cho HJ; Baek KE; Park SM; Kim IK; Choi YL; Cho HJ; Nam IK; Hwang EM; Park JY; Han JY; Kang SS; Kim DC; Lee WS; Lee MN; Oh GT; Kim JW; Lee CW; Yoo J
Clin Cancer Res; 2009 Apr; 15(8):2612-9. PubMed ID: 19351766
[TBL] [Abstract][Full Text] [Related]
18. FBXL5 attenuates RhoGDI2-induced cisplatin resistance in gastric cancer cells.
Wu WD; Wang M; Ding HH; Qiu ZJ
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(12):2551-7. PubMed ID: 27383304
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of RhoGDI2 mediated lung cancer epithelial-mesenchymal transition suppression.
Niu H; Wu B; Jiang H; Li H; Zhang Y; Peng Y; He P
Cell Physiol Biochem; 2014; 34(6):2007-16. PubMed ID: 25562149
[TBL] [Abstract][Full Text] [Related]
20. Depletion of RhoGDI2 expression inhibits the ability of invasion and migration in pancreatic carcinoma.
Yi B; Hu Y; Qin G; Gu W; Zhu X; He S; Zhou J; Li D
Int J Mol Med; 2014 Jul; 34(1):205-12. PubMed ID: 24788627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
